Sema3A could therefore represent a valuable prognostic marker for ovarian cancers; moreover, its activity could be potentially exploited for therapeutic approaches, currently validated in other preclinical tumor models in mice 54,55, as discussed later in this review. This evidence concerns the gene SEMA3A and ovarian carcinoma.